Rxcurve
HCPCS J9072 · per 5 MG

Inj cyclophos frindovyx 5 mg

Products billed under this code include Cyclophosphamide, Frindovyx.

Payment limit per 5 MG, by effective quarter, 2Q25 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.

Products billed under J9072

From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.

ProductLabelerNDCUnits / pkgLimit / pkg
Cyclophosphamide Avyxa Pharma, LLC 83831-0116-01 100 $812.00
Cyclophosphamide Avyxa Pharma, LLC 83831-0117-02 200 $1,624.00
Cyclophosphamide Avyxa Pharma, LLC 83831-0118-04 400 $3,248.00
Frindovyx Avyxa Pharma, LLC 83831-0119-01 100 $812.00
Frindovyx Avyxa Pharma, LLC 83831-0120-02 200 $1,624.00
Frindovyx Avyxa Pharma, LLC 83831-0121-04 400 $3,248.00

Every quarter

QuarterPayment limitChangeBilling unitDescriptionSource file
4Q26 $8.12 −$0.802 5 MG Inj cyclophos frindovyx 5 mg v1, posted September 17, 2026
3Q26 $8.922 −$0.181 5 MG Inj cyclophos frindovyx 5 mg v1, posted September 15, 2026
2Q26 $9.103 +$0.112 5 MG Inj cyclophos frindovyx 5 mg v1, posted September 15, 2026
1Q26 $8.991 −$0.114 5 MG Inj cyclophos frindovyx 5 mg v1, posted September 15, 2026
4Q25 $9.105 +$0.102 5 MG Inj cyclophos frindovyx 5 mg v1, posted September 8, 2026
3Q25 $9.003 −$0.05 5 MG Inj cyclophos avyxa 5mg v1, posted March 10, 2026
2Q25 $9.053 – 5 MG Inj cyclophos avyxa 5mg v1, posted March 10, 2026

“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.

CMS source files